Government denies it is considering limiting timber exports due to shortage
NZ’s structural timber shortage is the worst in living memory, says Building Industry Federation CEO Julien Leys.
Global
Stock Analysis
Frontdoor Announces Second-Quarter 2021 Revenue Increase of 11 Percent to $462…
[ This article was originally published here ]MEMPHIS, Tenn.–(BUSINESS WIRE)–Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading…
Eneti to Become Leading Wind Turbine Installation Vessel Company with Acquisition of Seajacks
Emanuele Lauro shocked the shipping industry and Wall Street last summer when he announced that Scorpio Bulkers, the NYSE-listed…
Thousands of People Were Given Heart Pumps Despite FDA Warnings of Defects
The FDA has relied on device makers to fix problems voluntarily rather than compelling them to do so.
Qualcomm wants to buy Veoneer for $4.6B, beating Magna’s offer – TechCrunch
The $3.8 billion sale of Swedish automotive tech company Veoneer to Magna International hit a roadblock Thursday after chipmaker…
Meet The Demand For Semiconductors With These Three Stocks
If you are looking for companies that supply a key component for vehicles, 5G and the Internet of Things, consider these three…
News24.com | Nigerian CEOs among best paid in sub-Saharan Africa – report
Chief executives of Nigerian-listed companies are among sub-Saharan Africa’s highest earners, according to a new report by PwC….
ZYMERGEN SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Zymergen Inc. – ZY
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C….
fuboTV: High-Risk, High-Reward
fuboTV offers a replacement to traditional TV services via streaming. The company has plenty of risks, but I would recommend…
Lexicon Pharmaceuticals Still On The Launch Pad, With An Uncertain Trajectory
The biggest news item from Lexicon’s second quarter report was a delay in expected results from the company’s Phase II studies…